(, , ) said its Parsortix liquid biopsy system has demonstrated the ability to isolate circulating tumour cells (CTCs) in three cancer studies at the Medical University of Vienna.
The studies in ovarian cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients all used Parsortix to isolate CTCs from a simple blood draw.
ANGLE said the studies demonstrate that CTC analysis before and during treatment can provide non-invasive monitoring of cancer patients throughout their treatment and that CTC gene expression profiles can determine progression free survival and response to therapy.
The largest study, a Phase II drug trial involving 133 ovarian cancer patients, explored longitudinal gene expression of CTCs isolated using the Parsortix system in platinum-resistant patients enrolled on the GANNET53 trial over a five-year period with an average four time points for each patient.
